News & Updates

Show Multimedia Only

Eloralintide looks good for obesity

Treatment with the novel selective amylin receptor agonist eloralintide results in substantial, dose-dependent reductions in bodyweight in adults with obesity, according to a phase II trial.

Eloralintide looks good for obesity

17 hours ago

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

a day ago

Treatment with cilofexor in patients with noncirrhotic primary sclerosing cholangitis (PSC) does not appear to reduce the rate of fibrosis progression, according to a phase III study.

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

a day ago

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

a day ago by

Combination treatment with sodium bicarbonate plus diphenhydramine may provide better symptom relief for patients with acute peripheral vertigo compared with diphenhydramine alone, as shown in a study.

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

a day ago

Vedolizumab better used in early- vs late-stage Crohn’s disease

a day ago

In patients with Crohn’s disease (CD), initiating treatment with vedolizumab early than late in the disease course may lead to better safety and efficacy outcomes, according to a phase IV open-label cohort study.

Vedolizumab better used in early- vs late-stage Crohn’s disease

a day ago

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

a day ago by

The novel glycoprotein IIb/IIIa inhibitor zalunfiban, administered at first medical contact in patients having ST-elevation myocardial infarction (STEMI), enhances patency of the infarct-related artery upon arrival in the catheterisation laboratory, in the phase III CeleBrate trial. It also improves 30-day cardiovascular (CV) outcomes, without increasing major bleeding.

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

a day ago

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025 by

Treatment with semaglutide appears to improve glycaemic control and weight outcomes in patients with schizophrenia receiving second-generation antipsychotics, as shown in a study.

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

12 Dec 2025

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

Treatment with rifaximin appears to provide no benefits in terms of 12-month survival or incidence of complications of cirrhosis in patients with severe cirrhosis and low ascitic fluid protein levels, a recent study has shown.

Rifaximin does not improve survival in severe cirrhosis

12 Dec 2025

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025 by

Both patients and healthcare professionals prefer treatment for asthma attacks that avoids the side effects of oral corticosteroids (OCS), and both are willing to trade off benefits, according to a study.

HCPs, patients willing to trade off OCS benefits to avoid side effects

12 Dec 2025

Doxycycline shows potential schizophrenia-lowering benefit

12 Dec 2025

Psychiatric patients exposed to doxycycline appear to have a reduced risk of schizophrenia, according to a study.

Doxycycline shows potential schizophrenia-lowering benefit

12 Dec 2025

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

A trend toward increased continuous use of tumour necrosis factor inhibitors has been observed throughout gestation, which suggests growing confidence in the safety and effectiveness of this medication during pregnancy, reveals a study.

Continuous use of TNFi on the rise in pregnant women

11 Dec 2025

News & Updates

Filter by Specialty:

Specialty:

Eloralintide looks good for obesity

Eloralintide looks good for obesity

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

Cilofexor does not halt fibrosis progression in noncirrhotic PSC

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

Sodium bicarbonate–diphenhydramine combo beneficial in acute peripheral vertigo

Vedolizumab better used in early- vs late-stage Crohn’s disease

Vedolizumab better used in early- vs late-stage Crohn’s disease

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

Prehospital zalunfiban improves arterial patency, 30-day outcomes in STEMI

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Semaglutide mitigates cardiometabolic burden in schizophrenia patients on second-gen antipsychotics

Rifaximin does not improve survival in severe cirrhosis

Rifaximin does not improve survival in severe cirrhosis

HCPs, patients willing to trade off OCS benefits to avoid side effects

HCPs, patients willing to trade off OCS benefits to avoid side effects

Doxycycline shows potential schizophrenia-lowering benefit

Doxycycline shows potential schizophrenia-lowering benefit

Continuous use of TNFi on the rise in pregnant women

Continuous use of TNFi on the rise in pregnant women